Evaluating Evolution of Incidence Rates of Hodgkin Lymphoma Subtypes

Share this content:

the Cancer Therapy Advisor take:

Recent declines in nodular sclerosis (NS) rates represented true incidence changes, whereas long-term rate decreases for mixed cellularity (MC) and increases for non-otherwise specified (NOS) Hodgkin lymphoma (HL) were attributed to evolutions in diagnostic and/or classification practices, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.

In this study, the investigators analyzed detailed histology-specific HL incidence rates from 1992 through 2011 using U.S. SEER data (n=21,372) and NOS pathology reports (regional subset from 2007-2011) for insight into diagnostic and classification practices.

Results showed cHL rates that were previously stable decreased after 2007 for whites [annual percent change (APC) and 95% CI: -3.6% (-5.6%, -1.5%)]. Similarly, a decline was observed in NS rates after 2007 by 5.9% annually, varying by gender, age, and race/ethnicity.

Furthermore, between 1992 and 2011, the overall incidence rates for MC and NOS declined (APC -4.0% [-4.7%, -3.3%]) and rose (5.3% [4.5%, 6.2%]), respectively.

There was minimal observation of trends in combined rates, suggesting increasing misclassification of MC, LD, and specific NS subtypes as NOS.

Out of 165 reviewed NOS pathology reports, 88 addressed classification choice. From these 88, 20 (12.1%) justified the classification, 21 (12.7%) had insufficient biopsy material, and 27 (16.4%) reported coders missed specific subtype information.

Obinutuzumab combined with bendamustine improved progression-free survival in rituximab-refractory i
Recent declines in nodular sclerosis rates represented true incidence changes in Hodgkin lymphoma.
Histologic subtypes of classical Hodgkin lymphoma (cHL) (e.g., nodular sclerosis (NS), mixed cellularity (MC), not otherwise specified (NOS)) are epidemiologically and prognostically distinctive. 
READ FULL ARTICLE From cebp.aacrjournals.org

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters